James Quigley
Stock Analyst at Morgan Stanley
(1.56)
# 3,506
Out of 5,109 analysts
25
Total ratings
33.33%
Success rate
3.88%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $83.33 | +52.41% | 7 | Dec 9, 2025 | |
| NVO Novo Nordisk | Maintains: Buy | $60 → $54 | $52.56 | +2.74% | 1 | Nov 28, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $138.88 | -15.03% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $48.36 | +34.41% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $9.03 | +16.28% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $32.99 | +21.25% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.13 | +411.18% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $83.33
Upside: +52.41%
Novo Nordisk
Nov 28, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $52.56
Upside: +2.74%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $138.88
Upside: -15.03%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $48.36
Upside: +34.41%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $9.03
Upside: +16.28%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $32.99
Upside: +21.25%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.13
Upside: +411.18%